Multiple Myeloma – Landscape & Forecast – Disease Landscape & Forecast (G7)

Treatment of multiple myeloma is complex. It involves a combination of proteasome inhibitors and/or immunomodulatory drugs (IMiDs) with chemotherapy. Treatment may also include cell-surface-targeted agents (e.g., Johnson & Johnson Innovative Medicine’s Darzalex) or other chemotherapy-based regimens. The preferred first-line treatment is bortezomib combined with lenalidomide and dexamethasone. CAR T-cell therapies (e.g., Bristol Myers Squibb / Bluebird Bio’s Abecma, Johnson & Johnson Innovative Medicine / Legend Biotech’s Carvykti) and bispecific antibodies (e.g., Johnson & Johnson Innovative Medicine’s Tecvayli and Talvey, Pfizer’s Elrexfio) have expanded the options available for R/R disease. Therapies in late-phase development will, if approved, further fragment the treatment of multiple myeloma.

Questions answered

• What is the size of the key drug-treatable populations? How will drug-treatment rates change over the 2023-2033 forecast period?
• How will the current treatment landscape change over the forecast period, and what impact will generic entry have on the market?
• Which emerging therapies are the most promising for multiple myeloma?
• What factors are driving the growth of the multiple myeloma therapy market, and how will it evolve over the forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.